Download to read offline
Uploaded byFiona Nielsen
Session 3 - big (biomedical) data
The document outlines a panel discussion at the Pistoia Alliance European Conference 2016 focused on big biomedical data, addressing challenges such as data collection, storage, and analysis. It emphasizes the growing interest in various 'omics' fields and the complexities of international collaboration, privacy concerns, and potential for breakthroughs in genomics. Key speakers included experts from 23andMe, MedImmune, and Osthus who discussed uncovering value from big data in biomedical research.
More Related Content
Similar to Session 3 - big (biomedical) data
More from Fiona Nielsen
Session 3 - big (biomedical) data
- 1. Big (Biomedical) Data Paneldiscussion • (Chair) Fiona Nielsen, CEO, DNAdigest and Repositive • Adam Auton, Senior Statistical Geneticist, 23andMe • Mathew Woodwark, Director of Research Bioinformatics, MedImmune • Eric Little, VP Data Science, Osthus
- 2. ©PistoiaAlliance Big Biomedical Data– chair introduction Pistoia Alliance European Conference 2016 220 April, 2016 • Fiona Nielsen, CEO of DNAdigest and Repositive
- 3. ©PistoiaAlliance Big Biomedical Data– intro Pistoia Alliance European Conference 2016 320 April, 2016 • High throughput technologies – biology is moving from the lab to the computer 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 Genomes Sequenced 80+PB Sequenced every year
- 4. ©PistoiaAlliance Big Biomedical Data– intro Pistoia Alliance European Conference 2016 420 April, 2016 • Growing interest and growing databanks
- 5. ©PistoiaAlliance Big Biomedical Data– intro Pistoia Alliance European Conference 2016 520 April, 2016 • Genomics, Proteomics, metabolomics, all the omics!
- 6. ©PistoiaAlliance Big Biomedical Data– intro Pistoia Alliance European Conference 2016 620 April, 2016 • Challenges in all dimensions of big data: Volume, Velocity, Variety, Veracity
- 7. ©PistoiaAlliance Big Biomedical Data– intro Pistoia Alliance European Conference 2016 720 April, 2016 Assay Types Dedicated to…
- 8. ©PistoiaAlliance Big Biomedical Data– intro Pistoia Alliance European Conference 2016 820 April, 2016 1 10 100 1000 10000 100000 1000000 Sample#(Log10) Top 5: GEO (1.8M) PMI Cohort Program (1M) Auria Biopankki (1M) EGA (~0.6M) SRA (~0.5M)
- 9. ©PistoiaAlliance Big Biomedical Data– intro Pistoia Alliance European Conference 2016 920 April, 2016 Aboriginals African Americans Africans Australians Chinese Malays Indians Danish Dutch Estonian Russian European Ancestry Finnish Icelandic Japanese Korean Latin Americans Saudi Swedish
- 10. ©PistoiaAlliance Big Biomedical Data– intro Pistoia Alliance European Conference 2016 1020 April, 2016 947560 0 8 8 66 0 2 6 6 8 50 62 3 2 5 0 0 2 3 International Interesting site to look at: http://omicsmaps.com/stats
- 11. ©PistoiaAlliance Big Biomedical Data– intro Pistoia Alliance European Conference 2016 1120 April, 2016 • Challenges in all dimensions of big data: How to collect? How to store? How to analyse?
- 12. ©PistoiaAlliance Big Biomedical Data– intro Pistoia Alliance European Conference 2016 1220 April, 2016 • Challenges for international research community: How to work across borders and silos?
- 13. ©PistoiaAlliance Big Biomedical Data– intro Pistoia Alliance European Conference 2016 1320 April, 2016 • Additional challenges for biomedical: Data privacy, data governance, patient consent, medical legislation
- 14. ©PistoiaAlliance Big Biomedical Data– intro Pistoia Alliance European Conference 2016 1420 April, 2016 • How will the landscape change when genomics moves to the clinic? ?
- 15. ©PistoiaAlliance Big Biomedical Data– intro Pistoia Alliance European Conference 2016 1520 April, 2016 • Is Big Data a promise of Big Findings? ?
- 16. ©PistoiaAlliance Big Biomedical Data– intro Pistoia Alliance European Conference 2016 1620 April, 2016 • Community-led databanks: patient groups, academia, the general public
- 17. ©PistoiaAlliance Big Biomedical Data– intro Pistoia Alliance European Conference 2016 1720 April, 2016 • For our panel discussion: • How can Pistoia Alliance members uncover value from Big Biomedical Data?
- 18. ©PistoiaAlliance Big (Biomedical) Datapanel speakers: Pistoia Alliance European Conference 2016 1820 April, 2016 Adam Auton Senior Statistical Geneticist, 23andMe Mathew Woodwark Director of Research Bioinformatics, MedImmune Eric Little VP Data Science, Osthus
- 19. ©PistoiaAlliance Thanks to ourpanel speakers: Pistoia Alliance European Conference 2016 1920 April, 2016 Adam Auton Senior Statistical Geneticist, 23andMe Mathew Woodwark Director of Research Bioinformatics, MedImmune Eric Little VP Data Science, Osthus
Editor's Notes
- #3 Chair to introduce self and personal connection with subject of the panel (2 min)
- #4 Falling cost of sequencing and techological advances General intro to the subject – assume audience are novices but from technical background What’s hot, what’s not Major recent advances Key tactical challenges Strategic issues faced Relevance to Pistoia Alliance activity and strategy (if appropriate)
- #5 General intro to the subject – assume audience are novices but from technical background What’s hot, what’s not Major recent advances Key tactical challenges Strategic issues faced Relevance to Pistoia Alliance activity and strategy (if appropriate)
- #6 General intro to the subject – assume audience are novices but from technical background What’s hot, what’s not Major recent advances Key tactical challenges Strategic issues faced Relevance to Pistoia Alliance activity and strategy (if appropriate)
- #7 General intro to the subject – assume audience are novices but from technical background What’s hot, what’s not Major recent advances Key tactical challenges Strategic issues faced Relevance to Pistoia Alliance activity and strategy (if appropriate)
- #8 General intro to the subject – assume audience are novices but from technical background What’s hot, what’s not Major recent advances Key tactical challenges Strategic issues faced Relevance to Pistoia Alliance activity and strategy (if appropriate)
- #9 General intro to the subject – assume audience are novices but from technical background What’s hot, what’s not Major recent advances Key tactical challenges Strategic issues faced Relevance to Pistoia Alliance activity and strategy (if appropriate)
- #10 General intro to the subject – assume audience are novices but from technical background What’s hot, what’s not Major recent advances Key tactical challenges Strategic issues faced Relevance to Pistoia Alliance activity and strategy (if appropriate)
- #11 General intro to the subject – assume audience are novices but from technical background What’s hot, what’s not Major recent advances Key tactical challenges Strategic issues faced Relevance to Pistoia Alliance activity and strategy (if appropriate)
- #12 General intro to the subject – assume audience are novices but from technical background What’s hot, what’s not Major recent advances Key tactical challenges Strategic issues faced Relevance to Pistoia Alliance activity and strategy (if appropriate)
- #13 How to advance research without impeding commercial incentives? Potential for pre-competitive collaborations? General intro to the subject – assume audience are novices but from technical background What’s hot, what’s not Major recent advances Key tactical challenges Strategic issues faced Relevance to Pistoia Alliance activity and strategy (if appropriate)
- #14 General intro to the subject – assume audience are novices but from technical background What’s hot, what’s not Major recent advances Key tactical challenges Strategic issues faced Relevance to Pistoia Alliance activity and strategy (if appropriate)
- #15 In the light of the increasing costs of drug development, this is an opportunity not to miss! General intro to the subject – assume audience are novices but from technical background What’s hot, what’s not Major recent advances Key tactical challenges Strategic issues faced Relevance to Pistoia Alliance activity and strategy (if appropriate)
- #16 In the light of the increasing costs of drug development, this is an opportunity not to miss! General intro to the subject – assume audience are novices but from technical background What’s hot, what’s not Major recent advances Key tactical challenges Strategic issues faced Relevance to Pistoia Alliance activity and strategy (if appropriate)
- #17 DNA.land OpenSNP PersonalGenomesProject Direct to consumer genetic tests & microbiome General intro to the subject – assume audience are novices but from technical background What’s hot, what’s not Major recent advances Key tactical challenges Strategic issues faced Relevance to Pistoia Alliance activity and strategy (if appropriate)
- #18 General intro to the subject – assume audience are novices but from technical background What’s hot, what’s not Major recent advances Key tactical challenges Strategic issues faced Relevance to Pistoia Alliance activity and strategy (if appropriate)
- #19 Template – panel self-introductions (1 min each)
- #20 Template – panel self-introductions (1 min each)